雷、环、痢方案根治幽门螺杆菌感染临床疗效观察(附134例报告)

目的　观察雷尼替丁、环丙沙星、痢特灵三联对幽门螺杆菌 (Hp)阳性的消化性溃疡、慢性胃炎患者的Hp根除率及对消化性溃疡的治疗效果。方法　经快速尿素酶试验及胃粘膜活检均确认有Hp感染的消化性溃疡、慢性胃炎患者共 15 5例 ,用雷尼替丁、环丙沙星、痢特灵三联与改良的经典三联 (果胶铋、四环素、痢特灵 )作随机对照治疗。治疗组进入临床试验病例 79例 ,疗效评价 6 8例。对照组进入试验病例 76例 ,疗效评价 6 6例。结果　治疗组与对照组Hp根除率分别为 88 2 % ( 6 0 /6 8)与 84 8% ( 5 6 /6 6 )。消化性溃疡临床愈合率分别为 81 7%与 6 5 6 % ,总有效率分别为 97 2 %与81 3 %。不良反应发生率分别为 4 4%与 14 9% ,上述结果经统计学比较Hp根除率两组差异无显著性 (P >0 0 5 ) ,消化性溃疡愈合率及总有效率、不良反应发生率差异有显著性 (P <0 0 5 )。结论　雷尼替丁、环丙沙星、痢特灵三联为一效好、价廉、不良反应少的治疗方案。

Eradication of Helicobacter pylori infection with ranitidine,ciprofloxacin and furazolidone plan --A clinical trial with 134 cases

Aims To assess the eradication rate of Hp with ranitidine,ciprofloxacin,furazolidone triple therapy in Hp possitive peptic ulcer and chronic gastritis patients.Methods 155 Hp positive patients with peptic ulcer or chronic gastritis were randomized to either RCF triple (ranitidine,ciprofloxacin,furazodidone) or modified standard triple(collordal bismuth pectin,furazolidone,tetracycline) as control.Hp infection was assessed by urease test and histology before treatment and four weeks after cessation of treatment.Restults Among the 155 cases assigned, 134 completed the trial.The eradication rates of Hp in RCF group and in control group were 88.2%(60/68)and 84%(56/60)respectively,showing no statistical difference ( P >0.05).In RCF group,the healing rate of peptic ulcer(81.7%,29/36) and total effective rate (97.2%,35/36) were significantly higher ( P <0.05) than that of control group (65.6%,21/36) and (81.3% 26/32) respectively,while the side effects in RCF group(4.4%,3/68) were significantly lower ( P <0.05) than that in control group (14.9%,10/67).Conclusions The RCF triple is a effective,economic plan with less side effects